The Shotlee Journal
Browse Shotlee articles about Health & Wellness.
Showing 9 / 258 Health & Wellness articles
The revolutionary GLP-1 medications have transformed weight management, but the journey of innovation continues. Discover how upcoming drugs aim to enhance patient experience and outcomes.
The FDA has issued a critical update to the drug facts label for Alli, the only over-the-counter weight loss medication available in the U.S. The changes highlight rare but potentially severe kidney-related side effects, prompting new warnings for consumers.
The journey to weight loss can be challenging, and for many, advanced medications like GLP-1 injectables offer a crucial pathway. However, their high cost often presents a significant barrier. Hers is changing this landscape by making popular GLP-1 and other weight loss treatments more accessible and affordable than ever before.
Tennis legend Serena Williams is making waves both on and off the court. As she returns to professional tennis, advertisements featuring her advocacy for GLP-1 medications are set to air, highlighting a significant cultural moment for weight management therapies.
Actress Mayim Bialik's recent experience with severe gastrointestinal distress after starting a GLP-1 medication has brought a critical conversation to the forefront: the reality of significant side effects associated with these popular drugs. While GLP-1s offer profound benefits for many, understanding and managing potential adverse reactions is paramount.
GLP-1 medications, initially developed for diabetes, are revolutionizing health outcomes, offering remarkable benefits for inflammation, joint pain, and even mental outlook, alongside significant weight loss.
A groundbreaking Stanford study reveals a genetic reason why approximately 10% of individuals don't respond as expected to GLP-1 receptor agonists, impacting treatments for diabetes and weight loss.
Pfizer's investigational GLP-1 receptor agonist, berobenatide, has shown promising results in Phase 2b trials for weight loss. This article delves into the data, its implications for obesity treatment, and what it means for Pfizer's investment outlook.
Mayim Bialik, known for her roles in 'Blossom' and 'The Big Bang Theory,' recently detailed her challenging journey with GLP-1 medications, highlighting severe gastrointestinal distress and other debilitating symptoms. Her candid account serves as a crucial reminder about the potential risks and the importance of careful medical supervision when considering these powerful drugs.
